How can we design better vaccines to prevent HIV infection in women?

Frontiers in Microbiology

Volumn 5, Issue OCT, 2014, Pages

  Rafferty, Hannah ^a   Sibeko, Sengeziwe ^a   Rowland Jones, Sarah ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Genital tract; HIV; Mucosal; Vaccines; Women

Indexed keywords

ADENOVIRUS VECTOR; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT;

ANTIGEN PRESENTING CELL; ARTICLE; CELL HOMING; CLINICAL TRIAL (TOPIC); CYTOKINE RESPONSE; FEMALE GENITAL SYSTEM; HORMONE ACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOID TISSUE; MENSTRUAL CYCLE; MUCOSAL ADMINISTRATION; MUCOSAL IMMUNITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; UTERINE CERVIX MUCOSA; VAGINA DISCHARGE;

EID: 84910092343     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00572     Document Type: Article

References (81)

1. Magadi MA. Understanding the gender disparity in HIV infection across countries in sub-Saharan Africa: evidence from the Demographic and Health Surveys. Sociol Health Illn. 2011 May;33(4):522-39.
2. UNAIDS. 2012 UNAIDS Report on the Global AIDS Epidemic. Global Report. 2012.
3. Baral S, Beyrer C, Muessig K, Poteat T, Wirtz AL, Decker MR, et al. Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Jul;12(7):538-49.
4. Kalichman SC, Pinkerton SD, Carey MP, Cain D, Mehlomakulu V, Carey KB, et al. Heterosexual anal intercourse and HIV infection risks in the context of alcohol serving venues, Cape Town, South Africa. BMC Public Health. 2011;11:807.
5. UNAIDS. Women Outloud: How Women Living with HIV will Help the World End AIDS2012.
6. Boily MC, Baggaley RF, Masse B. The role of heterosexual anal intercourse for HIV transmission in developing countries: are we ready to draw conclusions? Sex Transm Infect. 2009 Oct;85(6):408-10.
7. Rodriguez-Garcia M, Patel MV, Wira CR. Innate and adaptive anti-HIV immune responses in the female reproductive tract. J Reprod Immunol. 2013 Mar;97(1):74-84.
8. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990 Apr;80(4):460-2.
9. Government of Uganda. Uganda: UNGASS Country Progress Report. 2008.
10. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and metaanalysis. PLoS Med. 2014 Feb;11(2):e1001608.
11. Nuovo GJ, Forde A, MacConnell P, Fahrenwald R. In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues. Am J Pathol. 1993 Jul;143(1):40-8.
12. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod. 2005 Dec;73(6):1253-63.
13. Hwang LY, Scott ME, Ma Y, Moscicki AB. Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol. 2011 Jan;88(1):66-71.
14. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, MacDonald KS, et al. Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS. 2009 Jan 28;23(3):309-17.
15. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, et al. Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis. 2012 Oct 1;206(7):993-1001.
16. Yeaman GR, Guyre PM, Fanger MW, Collins JE, White HD, Rathbun W, et al. Unique CD8+ T cell-rich lymphoid aggregates in human uterine endometrium. J Leukoc Biol. 1997 Apr;61(4):427-35.
17. Perry LL, Feilzer K, Portis JL, Caldwell HD. Distinct homing pathways direct T lymphocytes to the genital and intestinal mucosae in Chlamydia-infected mice. J Immunol. 1998 Mar 15;160(6):2905-14.
18. Kantele A, Häkkinen M, Moldoveanu Z, Lu A, Savilahti E, Alvarez RD, et al. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infection and immunity. 1998;66(12):5630-5.
19. Mestecky J, Russell MW. Induction of mucosal immune responses in the human genital tract. FEMS Immunol Med Microbiol. 2000 Apr;27(4):351-5.
20. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, Wallenstein S, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS. 2007 Feb 19;21(4):467-76.
21. Fahey JV, Wright JA, Shen L, Smith JM, Ghosh M, Rossoll RM, et al. Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture. Mucosal Immunol. 2008 Jul;1(4):317-25.
22. Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, Adams DR, et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):261-4.
23. Wira CR, Fahey JV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS. 2008 Oct 1;22(15):1909-17.
24. Radtke AL, Quayle AJ, Herbst-Kralovetz MM. Microbial Products Alter the Expression of Membrane-Associated Mucin and Antimicrobial Peptides in a Three-Dimensional Human Endocervical Epithelial Cell Model 1. Biology of reproduction. 2012;87(6).
25. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med. 2011;62:127-39.
26. Miller CJ. Localization of Simian immunodeficiency virus-infected cells in the genital tract of male and female Rhesus macaques. J Reprod Immunol. 1998 Dec;41(1-2):331-9.
27. Li Q, Skinner PJ, Ha SJ, Duan L, Mattila TL, Hage A, et al. Visualizing antigenspecific and infected cells in situ predicts outcomes in early viral infection. Science. 2009 Mar 27;323(5922):1726-9.
28. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009;458(7241):1034-8.
29. Norvell MK, Benrubi GI, Thompson RJ. Investigation of microtrauma after sexual intercourse. J Reprod Med. 1984 Apr;29(4):269-71.
30. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999 Nov 12;286(5443):1353-7.
31. Gupta P, Collins KB, Ratner D, Watkins S, Naus GJ, Landers DV, et al. Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol. 2002 Oct;76(19):9868-76.
32. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature. 2009 Mar 4.
33. Belec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Diallo MO, et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis. 2001 Dec 1;184(11):1412-22.
34. Broliden K, Hinkula J, Devito C, Kiama P, Kimani J, Trabbatoni D, et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett. 2001 Nov 1;79(1-2):29-36.
35. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol. 2000 Nov 1;165(9):5170-6.
36. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):413-20.
37. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS. 2000 Sep 8;14(13):1917-20.
38. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006 Jan 2;20(1):73-83.
39. Mazzoli S, Trabbatoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med. 1997;3(11):1250-7.
40. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2009 Sep;2(5):412-26.
41. Kaul R, Plummer F, Clerici M, Bomsel M, Lopalco L, Broliden K. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS. 2001 Feb 16;15(3):431-2.
42. Buchacz K, Parekh BS, Padian NS, van der Straten A, Phillips S, Jonte J, et al. HIVspecific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men. AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1689-93.
43. Dorrell L, Hessell AJ, Wang M, Whittle H, Sabally S, Rowland-Jones S, et al. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia [In Process Citation]. Aids. 2000;14(9):1117-22.
44. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, et al. HIV-1-Specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1- resistant prostitutes in nairobi [In Process Citation]. J Immunol. 2000;164(3):1602-11.
45. Kaul R, Thottingal P, Kimani J, Kiama P, Waigwa CW, Bwayo JJ, et al. Quantitative ex vivo analysis of functional virus-specific CD8 T lymphocytes in the blood and genital tract of HIV-infected women. Aids. 2003 May 23;17(8):1139-44.
46. Iqbal SM, Ball TB, Kimani J, Kiama P, Thottingal P, Embree JE, et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis. 2005 Sep 1;192(5):728-38.
47. Card CM, Rutherford WJ, Ramdahin S, Yao X, Kimani M, Wachihi C, et al. Reduced cellular susceptibility to in vitro HIV infection is associated with CD4+ T cell quiescence. PLoS One. 2012;7(9):e45911.
48. Lajoie J, Juno J, Burgener A, Rahman S, Mogk K, Wachihi C, et al. A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers. Mucosal Immunol. 2012 May;5(3):277-87.
49. Card CM, Ball TB, Fowke KR. Immune Quiescence: a model of protection against HIV infection. Retrovirology. 2013 Nov 20;10(1):141.
50. McLaren PJ, Ball TB, Wachihi C, Jaoko W, Kelvin DJ, Danesh A, et al. HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. J Infect Dis. 2010 Nov 1;202 Suppl 3:S339-44.
51. Songok EM, Luo M, Liang B, McLaren P, Kaefer N, Apidi W, et al. Microarray analysis of HIV resistant female sex workers reveal a gene expression signature pattern reminiscent of a lowered immune activation state. PLoS One. 2012;7(1):e30048.
52. Cohen MS. HIV and sexually transmitted diseases: lethal synergy. Top HIV Med. 2004 Oct-Nov;12(4):104-7.
53. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 2010 Mar 11;464(7286):217-23.
54. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med. 1996;184(5):1879-90.
55. Ranasinghe C, Ramshaw IA. Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity. European journal of immunology. [Research Support, Non-U.S. Gov't]. 2009 Jul;39(7):1819-30.
56. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, Miranda C, et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One. [Research Support, Non-U.S. Gov't]. 2012;7(1):e29717.
57. Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1999 Nov;73(11):9609-13.
58. Pattani A, McKay PF, Garland MJ, Curran RM, Migalska K, Cassidy CM, et al. Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. Journal of controlled release: official journal of the Controlled Release Society. [Research Support, Non-U.S. Gov't]. 2012 Sep 28;162(3):529-37.
59. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine. 2007 Jul 26;25(30):5467-84.
60. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nature reviews Immunology. [Research Support, N.I.H., Extramural Review]. 2006 Feb;6(2):148-58.
61. Abdool Karim Q AKS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
62. Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, Moss B, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proceedings of the National Academy of Sciences of the United States of America. 1998 Feb 17;95(4):1709-14.
63. Imaoka K, Miller CJ, Kubota M, McChesney MB, Lohman B, Yamamoto M, et al. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1998 Dec 1;161(11):5952-8.
64. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infection and immunity. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1997 Jul;65(7):2676-84.
65. Pialoux G, Hocini H, Perusat S, Silberman B, Salmon-Ceron D, Slama L, et al. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study. Vaccine. [Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2008 May 19;26(21):2657-66.
66. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2011 Feb 25;34(2):269-80.
67. Leroux-Roels G, Maes C, Clement F, van Engelenburg F, van den Dobbelsteen M, Adler M, et al. Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One. [Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2013;8(2):e55438.
68. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012;491(7424):463-7.
69. Tregoning JS, Buffa V, Oszmiana A, Klein K, Walters AA, Shattock RJ. A "primepull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice. PLoS One. [Research Support, N.I.H., Extramural]. 2013;8(11):e80559.
70. Yuki Y, Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol. 2003 Sep-Oct;13(5):293-310.
71. Rainone V, Dubois G, Temchura V, Überla K, Clivio A, Nebuloni M, et al. CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particles. PLoS One. 2011;6(10):e26979.
72. Hu K, Luo S, Tong L, Huang X, Jin W, Huang W, et al. CCL19 and CCL28 Augment Mucosal and Systemic Immune Responses to HIV-1 gp140 by Mobilizing Responsive Immunocytes into Secondary Lymph Nodes and Mucosal Tissue. The Journal of Immunology. 2013;191(4):1935-47.
73. Ranasinghe C, Trivedi S, Stambas J, Jackson R. Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8+ T-cell avidity and protective immunity. Mucosal immunology. 2013;6(6):1068-80.
74. Buchbinder SP MD, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881-93.
75. Gordon SN, Kines RC, Kutsyna G, Ma Z-M, Hryniewicz A, Roberts JN, et al. Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. The Journal of Immunology. 2012;188(2):714-23.
76. Narimatsu R, Wolday D, Patterson BK. IL-8 increases transmission of HIV type 1 in cervical explant tissue. AIDS Research & Human Retroviruses. 2005;21(3):228-33.
77. Parker SD, Rottinghaus ST, Zajac AJ, Yue L, Hunter E, Whitley RJ, et al. HIV-1< sub> 89.6 Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice. Vaccine. 2007;25(37):6764-73.
78. Sibeko S, Makvandi-Nejad S. From the laboratory to clinical trials and back again: lessons learned from HIV prevention trials. Am J Reprod Immunol. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 2013 Feb;69 Suppl 1:106-15.
79. Hickey DK, Patel MV, Fahey JV, Wira CR. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. Journal of reproductive immunology. 2011;88(2):185-94.
80. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. The Journal of Immunology. 2002;169(1):566-74.
81. Madan RP, Carpenter C, Fiedler T, Kalyoussef S, McAndrew TC, Viswanathan S, et al. Altered biomarkers of mucosal immunity and reduced vaginal lactobacillus concentrations in sexually active female adolescents. PLoS One. 2012;7(7):e40415.